Skip to main content

Short Reads: Sep 1, 2001


Bring on the veeps! Exact Sciences hires Stephen Read from Renaissance Worldwide as VP and controller; David Nikka from Abiomed as VP of resources and development; and William Pignato from Bayer Diagnostics as VP of regulatory affairs.


Stephen Joseph resigned from his post as president and CEO at the bioinformatics-concentrated National Center for Genome Resources and is temporarily replaced by board member Miguel Rios, founder and CEO of Orion International Technologies. No word yet on a more permanent solution.


James Aswell, who’s been at Bayer for the past 10 years, joins Variagenics as senior director of diagnostics.


We wonder how they’ll split the letterhead. ProteoMetrics hired Doug Lockyer, a founder of Riptide Communications, as business CEO, while former CSO Ron Beavis becomes science CEO.


Affy shuffles its deck: Barbara Caulfield joins as executive VP and general counsel, replacing Vern Norviel. Norviel will take on the role of general counsel at subsidiary Perlegen. Also, Gregory Schiffman comes on as CFO for Affy, while current CFO Edward Hurwitz moves to senior vice president of corporate strategy and new ventures.


The business of bioinformatics: Dominic Clark climbs aboard at Generics Group, where he’ll develop the advisory, investment, and innovation services for bioinformatics. Clark was previously at Pharmagene and GlaxoWellcome.


Tod Lauerman joins Egea Biosciences as senior vice president of business development. He comes from Evotec, where he helped pen deals with Pharmacia, Amgen, Elan, and Immunex.


Enal Razvi popped up at DiscoveRx as vice president of business development. Razvi, a former Frost and Sullivan biotech analyst, has been at LJL Biosystems (now Molecular Devices) since 1998.


Word at the Copenhagen ISMB conference this year was that Gene Myers, Celera''s vice president for informatics research, was running uncontested for president of the International Society for Computational Biology.


Here’s to titles we’re not used to in the genomics field. Stratagene appoints Thomas Collins to VP of manufacturing, and Exelixis hires Jeffrey Latts as its chief medical officer.


The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.